Trademark: 88344838
Status Date
Monday, October 25, 2021
Filing Date
Monday, March 18, 2019
Published for Opposition
Tuesday, January 28, 2020
Abandoned Date
Monday, October 25, 2021
5 Immunosequencing-based assay kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, for detection of cancer, autoimmune disease and infection; medical diagnostic assay kits comprised of medical diagnostic reagents and assays for detecting cancer, autoimmune disease and infection; the aforementioned goods not in the field of or for use in the field of ocular diagnostics or treatment, including ophthalmology and optometry, and not for use in providing sales, marketing, or consulting services, including direct to consumer sales, direct to consumer marketing, and providing consulting services, in the field of ocular diagnostics or treatment
42 Medical laboratory services; the aforementioned services not in the field of or for use in the field of ocular diagnostics or treatment, including ophthalmology and optometry, and not for use in providing sales, marketing, or consulting services, including direct to consumer sales, direct to consumer marketing, and providing consulting services, in the field of ocular diagnostics or treatment
44 Providing medical diagnostic and prognostic testing for cancer, autoimmune disease and infection, and the analysis, evaluation, and reporting of those test results to help healthcare professionals determine a patient's clinical diagnosis, the effectiveness of patient treatments, and to revise future treatments accordingly; providing medical diagnostic and prognostic testing services; medical services; consulting services in the field of medical diagnostic testing; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; the aforementioned services not in the field of or for use in the field of ocular diagnostics or treatment, including ophthalmology and optometry, and not for use in providing sales, marketing, or consulting services, including direct to consumer sales, direct to consumer marketing, and providing consulting services, in the field of ocular diagnostics or treatment
Oct 25, 2021
Abandonment Notice E-Mailed - No Use Statement Filed
Oct 25, 2021
Abandonment - No Use Statement Filed
Mar 24, 2021
Notice Of Approval Of Extension Request E-Mailed
Mar 22, 2021
Extension 2 Granted
Mar 22, 2021
Extension 2 Filed
Mar 22, 2021
Teas Extension Received
Sep 17, 2020
Notice Of Approval Of Extension Request E-Mailed
Sep 15, 2020
Extension 1 Granted
Sep 15, 2020
Extension 1 Filed
Sep 15, 2020
Teas Extension Received
Mar 24, 2020
Noa E-Mailed - Sou Required From Applicant
Jan 28, 2020
Official Gazette Publication Confirmation E-Mailed
Jan 28, 2020
Published For Opposition
Jan 8, 2020
Notification Of Notice Of Publication E-Mailed
Dec 23, 2019
Assigned To Lie
Dec 20, 2019
Approved For Pub - Principal Register
Dec 3, 2019
Teas/Email Correspondence Entered
Dec 2, 2019
Correspondence Received In Law Office
Dec 2, 2019
Teas Response To Office Action Received
Jun 4, 2019
Notification Of Priority Action E-Mailed
Jun 4, 2019
Priority Action E-Mailed
Jun 4, 2019
Priority Action Written
May 28, 2019
Assigned To Examiner
Apr 5, 2019
New Application Office Supplied Data Entered In Tram
Mar 21, 2019
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
